Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Withdrawn 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 2Hematologic Neoplasms 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × CTLA-4 Antigen × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡